CDK2 and breast carcinoma: The second is identification of mechanistically sensitive tumors, which depend heavily on CDK9-dependent transcription of selected driver genes such as MCL1, MYC, MYCN, or which are reliant on dysregulated activation of CDK2/cyclin E. A good precedent for such patient selection is the identification of a specific breast cancer subset for CDK4/6 inhibitors [28].